title: Breast-conservation treatment for bilateral breast cancer in five Japanese women.
abstract: Between August 1989 and September 1999, breast-conservation treatment (BCT) was performed in 250 of 256 breast cancer patients. Five of the 250 patients had bilateral breast cancer, and 4 with synchronous bilateral breast cancer of the 5 were concomitantly treated by chemo-endocrine therapy before simultaneous breast-conservation surgery for bilateral breast cancer. Chemotherapy was performed using cyclophosphamide, pirarubicin, and 5-fluorouracil, while endocrine therapy was performed using an antiestrogen agent (tamoxifen or toremifene). All patients were also treated by radiotherapy. Since no severe side effects or complications were induced by these therapeutic approaches, bilateral breast cancer may be successfully treated by BCT as in unilateral breast cancer. However, of the 5 patients with bilateral breast cancer, cancer recurrence in the axillary lymph nodes was detected only in 1 patient with T2N1 cancer 78 months after simultaneous breast-conservation surgery for bilateral breast cancer.
authors.affiliation: Department of Radiology, Hosogi Hospital, Kochi 780-8535, Japan.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Hamada
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Akihito
authors.initials: A
authors.lastname: Nishioka
authors.forename: Shinji
authors.initials: S
authors.lastname: Kariya
authors.forename: Masako
authors.initials: M
authors.lastname: Terashima
authors.forename: Shoji
authors.initials: S
authors.lastname: Yoshida
authors.forename: Naoshige
authors.initials: N
authors.lastname: Tochika
authors.forename: Yohsuke
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Masamitsu
authors.initials: M
authors.lastname: Kumon
authors.forename: Taisuke
authors.initials: T
authors.lastname: Inomata
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000601:surgery*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D015412:Mastectomy, Segmental / Q000379:methods*; D008875:Middle Aged; D012008:Recurrence; D013629:Tamoxifen / Q000627:therapeutic use; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D017312:Toremifene / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D017312:Toremifene; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin; D005472:Fluorouracil